Health Care Equipment

Cortigent, Inc.

Cortigent, Inc. released FY2024 Q3 earnings on November 20 (EST) with actual revenue of 0 USD and EPS of -0.1204 USD

Cortigent, Inc. released FY2024 9 Months Earnings on November 20 (EST) with actual revenue of 0 USD and EPS of -0.3438 USD

Cortigent, Inc. released FY2023 Q3 earnings on November 20 (EST) with actual revenue of 0 USD and EPS of -0.2966 USD

Cortigent, Inc. released FY2023 9 Months Earnings on November 20 (EST) with actual revenue of 0 USD and EPS of -0.9502 USD

Cortigent, Inc. released FY2023 Q2 earnings on August 16, 2024 (EST) with actual revenue of 0 USD and EPS of -0.3066 USD

Cortigent, Inc. released FY2024 Semi-Annual Earnings on August 16 (EST) with actual revenue of 0 USD and EPS of -0.2234 USD

Cortigent, Inc. released FY2023 Semi-Annual Earnings on August 16 (EST) with actual revenue of 0 USD and EPS of -0.6536 USD

Cortigent, Inc. released FY2024 Q2 earnings on August 16 (EST) with actual revenue of 0 USD and EPS of -0.1064 USD

Cortigent, Inc. released FY2023 Q1 earnings on May 23 (EST) with actual revenue of 0 USD and EPS of -0.347 USD

Cortigent, Inc. released FY2024 Q1 earnings on May 23 (EST) with actual revenue of 0 USD and EPS of -0.117 USD

Cortigent, Inc. released FY2022 Q4 earnings on February 29, 2024 (EST), with actual revenue of 0 USD and EPS of -0.3312 USD

Cortigent, Inc. released FY2022 Q3 earnings on February 29, 2024 (EST), with actual revenue of 0 USD and EPS of -0.3312 USD

Cortigent, Inc. released FY2023 Annual Earnings on February 29, 2024 (EST) with actual revenue of 0 USD and EPS of -1.0984 USD

Cortigent, Inc. released FY2022 Annual Earnings on February 29, 2024 (EST) with actual revenue of 0 USD and EPS of -1.72 USD

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

CRGT

In response to increasing compliance demands in the healthcare AI industry worldwide, Corti has introduced the Startup Acceleration Program. This initiative aims to assist entrepreneurs in overcoming a regulatory obstacle of €600,000. The program also focuses on developing a vertical model that surpassed OpenAI on the latest healthcare benchmark. The launch took place in Copenhagen, Denmark on May 13, 2026.

Unusual Whales

iShares US Pharma

iShares Global Healthcare

Health Care Select Sector SPDR

OpenAI

Corti steps up its support for the next wave of healthcare startups as OpenAI pushes into the space and others retreat from Europe

CORT

Corti has launched its Startup Acceleration Program to support healthcare AI startups in overcoming regulatory barriers, particularly in Europe. The program offers access to its clinical-grade AI model, Symphony, which has outperformed OpenAI on HealthBench. With increasing compliance pressures, Corti aims to assist founders in navigating the complex regulatory landscape, providing resources and support to help them scale their innovations. Applications for the program are now open to pre-seed through Series B companies in healthcare and adjacent life sciences.

prnewswire

Corcept Therap

VG Health

Proshares Ultra Nasdaq Biotech

12:30 ETCorti steps up its support for the next wave of healthcare startups as OpenAI pushes into the space and others retreat from Europe

LABU

Vivani Medical received a Buy rating from Maxim Group analyst Naz Rahman, who set a price target of $4.00. Rahman cites the company's strong financial position, with no debt and sufficient funding to support operations until mid-2027. He also points to strategic catalysts, including a planned spin-off/IPO of Cortigent and the NPM-139 semaglutide implant program, which targets the obesity market with a convenient dosing schedule, as key factors supporting his positive outlook on the stock.

- Vivani Medical was reassessed by Wall Street analyst Naz Rahman from Maxim Group on March 27, who maintained a buy rating and set a target price of $4.00.  
- Rahman cites Vivani's strong financial foundation, substantial cash reserves, and lack of debt as key factors supporting operations until mid-2027, which helps mitigate short-term financing risks.  
- He also highlights potential value drivers, including a planned spin-off/IPO and the NPM-139 semaglutide implant program targeting the obesity market with a convenient biannual dosing regimen.

Cortigent, Inc.(CRGT.US)

Corti steps up its support for the next wave of healthcare startups as OpenAI pushes into the space and others retreat from Europe

12:30 ETCorti steps up its support for the next wave of healthcare startups as OpenAI pushes into the space and others retreat from Europe

Vivani: Solid Funding Runway and Strategic Catalysts Underpin Buy Rating